drugset / Trial / NCT07578584

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

NCT07578584 ↗

Phase 1 Recruiting 146 enrolled Novo Nordisk A/S
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this clinical study is to find out if NNC0497-0040 is safe, tolerable and effective for healthy people living with normal weight or overweight, people living with overweight or obesity and people who have type 1 diabetes and are living with overweight or obesity. There are 2 study treatments in this study, where participants will get either NNC0497-0040, the new treatment being tested or placebo, a treatment that has no active medicine in it. Participants will be in this clinical study for up to 29 weeks.

Timeline

Start
2026-05-07
Primary completion
2028-02-18
Completion
2028-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0497-0040 Unknown — Subcutaneous